Mainz Biomed (MYNZ) announced that its partner, GANZIMMUN Diagnostics, has officially launched the enhanced ColoAlert colorectal cancer screening test. Starting this January, patients across Germany can access this new version of the Company’s screening test, in time for Colorectal Cancer Awareness Month in March. First introduced by Mainz Biomed in mid-2024, the enhanced ColoAlert features advancements, including a proprietary DNA stabilizing buffer, to deliver accurate results even with varying sample volumes.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.